Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group.

Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, Cohen JM, Grandmottet P, Vague P, Safar ME, Eschwège E.

Diabetes Care. 1996 Sep;19(9):920-6.

PMID:
8875083
2.

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.

Palumbo PJ.

J Diabetes Complications. 1998 Mar-Apr;12(2):110-9. Review.

PMID:
9559489
3.

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.

Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT.

J Intern Med. 2004 Jul;256(1):1-14. Review.

5.

Beneficial effects of metformin on haemostasis and vascular function in man.

Grant PJ.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S44-52. Review.

PMID:
14502100
6.

Do effects on blood pressure contribute to improved clinical outcomes with metformin?

Schäfers RF.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S62-70. Review.

PMID:
14502102
7.

Biguanides and NIDDM.

Bailey CJ.

Diabetes Care. 1992 Jun;15(6):755-72. Review.

PMID:
1600835
8.

[Prevention and treatment for development and progression of diabetic macroangiopathy with pioglitazone and metformin].

Tamura H, Mokuno H, Daita H.

Nihon Rinsho. 2006 Nov;64(11):2119-25. Review. Japanese.

PMID:
17087306
9.

New drugs and clinical trials in diabetes and hypertension.

Nilsson P.

Exp Clin Endocrinol Diabetes. 1997;105 Suppl 2:64-9. Review.

PMID:
9288549
10.

Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.

Zimmet P, Collier G.

Drugs. 1999;58 Suppl 1:21-8; discussion 75-82. Review.

PMID:
10576521
11.

The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects.

Grant PJ.

Diabete Metab. 1991 May;17(1 Pt 2):168-73. Review.

PMID:
1936471
12.

Is metformin more than an oral hypoglycaemic agent?

Vague P.

Diabetes Metab. 2003 Sep;29(4 Pt 2):6S5-7. Review. No abstract available.

PMID:
14502095
13.
14.

Metformin and blood pressure.

Landin-Wilhelmsen K.

J Clin Pharm Ther. 1992 Apr;17(2):75-9. Review.

PMID:
1583082
15.

Remarks concerning some recent reports on therapy of diabetes.

Laubatières A.

Isr J Med Sci. 1972 Jun;8(6):883-7. Review. No abstract available.

PMID:
4559429
16.

[Identification and prevention of vascular risk. Significance of metformin].

Isnard F, André P.

Journ Annu Diabetol Hotel Dieu. 1990:311-23. Review. French. No abstract available.

PMID:
2195214
17.

Use of metformin in pediatric age.

Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M.

Pediatr Diabetes. 2011 Sep;12(6):580-8. doi: 10.1111/j.1399-5448.2010.00741.x. Epub 2011 Mar 3. Review. No abstract available.

PMID:
21366813
18.

Impact of Metformin on Exercise-Induced Metabolic Adaptations to Lower Type 2 Diabetes Risk.

Malin SK, Braun B.

Exerc Sport Sci Rev. 2016 Jan;44(1):4-11. doi: 10.1249/JES.0000000000000070. Review.

PMID:
26583801
19.

[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].

Satoh J.

Nihon Rinsho. 2003 Jul;61(7):1224-9. Review. Japanese.

PMID:
12877089
20.

Drugs and insulin resistance: clinical methods of evaluation and new pharmacological approaches to metabolism.

Donnelly R, Morris AD.

Br J Clin Pharmacol. 1994 Apr;37(4):311-20. Review. No abstract available.

Supplemental Content

Support Center